Immuno-oncology

#Cancer research #Data #Events #Immuno-oncology

GSK showcases advances in oncology at ASCO and EHA

GlaxoSmithKline (GSK) will present new data from key focus areas within its oncology portfolio at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (June 4-8) and the European Hematology Association (EHA) 2021 Virtual Congress (June 9-17). The company will present new data on its approved therapies, BLENREP… Read More

#News

#Biobanking #Imaging #Immuno-oncology #Online focus #PET technology #Pharma #Phenomics #Tumour biology

Multimodal PET yields novel insights in preclinical oncology

By Mette Lauritzen PhD, Product Marketing Manager, Nuclear Molecular Imaging, Bruker BioSpin Different types of tumours, and their varying reactions to treatment, make the search for new effective cancer therapies incredibly challenging. Preclinical in vivo imaging methods are helping to obtain further knowledge of tumour morphology, progression, and biomarker expression… Read More

#Exclusive Content #News

#Alzheimer's #Clinical trial #Drug development #Drug discovery #Drug targets #Immuno-oncology

Can this clinical trial move us closer to an Alzheimer’s treatment?

Exscientia has announced a Phase I clinical study of DSP-0038 in the US for the treatment of Alzheimer’s disease psychosis. DSP-0038 is the third molecule created using Exscientia’s Artificial Intelligence (AI) technologies to enter clinical trials. The two earlier compounds are DSP-1181, announced in 2020 together with Sumitomo Dainippon Pharma… Read More

#News

#Cancer research #Drug targets #Immuno-oncology #Oncology #Research #Vaccines

Personalised cancer vaccine 45% effective at targeting tumours

Researchers have developed an effective vaccine that re-engineers cells from a patient’s tumour to target and destroy cancer cells. The results, published in the peer-reviewed Journal of Clinical Oncology, show that 45% of patients treated with an autologous cell vaccine, created from their own cancer cells, had a confirmed anti-tumour… Read More

#News

#Checkpoint inhibitor therapies #Immuno-oncology #Immunotherapy

Insight into immuno-oncology and cancer immunotherapy drug discovery

Evaluation of checkpoint inhibitor therapies using an MLR assay, is an exclusive webinar that will be hosted by DDW and supported by Sartorius. It will provide valuable information for immuno-oncology research and the cancer immunotherapy drug discovery process. The event is now available to watch on demand here Sartorius recognises… Read More

#Editor's Choice #News

#AstraZeneca #Biotherapeutics #Drug discovery #Immuno-oncology

Biotech collaboration to accelerate prostate cancer research

Alchemab has collaborated with AstraZeneca to work on a proof-of-concept study to build understanding of the fundamental biology of prostate cancer. Under the agreement, Alchemab’s novel drug discovery platform will be used as a diagnostic tool through the identification of disease biomarkers with potential to inform the development of novel… Read More

#News

#Biotherapeutics #Cancer research #Drug development #Immuno-oncology #Pharmaceutical

Janssen seeks approval for refractory multiple myeloma drug

The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. Read More

#Cancer Research #News

#Antibody #Cancer #Immuno-oncology #Immunotherapy

Twist Biopharma: antibody candidates against GPCR therapeutic targets

Immunotherapy has the potential to treat a wide variety of conditions, from autoimmune disease to cancer. However, the discovery of potential antibody therapeutics against key receptor proteins remains a major challenge for the traditional immunisation approaches currently available on the market. Twist Biopharma, an arm of Twist Bioscience, was built… Read More

#Exclusive Content #News

#Drug discovery #Immuno-oncology #Immunotherapy #Webinar

Are you involved in immuno-oncology or cancer immunotherapy research?

This webinar, Evaluation of checkpoint inhibitor therapies using an MLR assay, is hosted by DDW and supported by Sartorius and will provide useful information for immuno-oncology research and the cancer immunotherapy drug discovery process. The event took place on 12 May. Watch for free here. In the field of immunotherapy… Read More

#Editor's Choice #News

#Biomarkers #Cancer research #Events #Immuno-oncology

Immodulon presents on clinical biomarker strategies

Immodulon, the immuno-oncology company, will present at the 11th World Clinical Biomarkers & Companion Diagnostic Europe Event taking place virtually 24-25 March 2021. The presentation, titled ‘Clinical Biomarker Strategy with a Complex Immunomodulator: The Must-Haves & the Nice-To-Haves On a Limited Budget’, will be presented at 12:45 CET, March 25, 2021,… Read More

#Cancer Research #News

#Immuno-oncology #T-Cells #Therapeutics

T-Cypher Bio separates from Orbit Discovery to build a pipeline of TCR therapeutics

T-Cypher Bio, a biotech company pioneering a novel approach to (T cell receptor) TCR therapeutics has separated from Orbit Discovery to focus on developing a functional, high-throughput, bead-display platform to select therapeutically relevant targets and identify potent, target-specific TCRs for the treatment of solid tumours and other indications. The formation… Read More

#News

#Cancer research #Immuno-oncology #Oncology

UCL and AstraZeneca collaborate on immuno-oncology research

Researchers from UCL Division of Infection & Immunity will lead on two collaborative projects with AstraZeneca. The projects’ long-term aim is to contribute to the development of new cancer treatments. These research collaborations will investigate immune checkpoints which are key biochemical pathways that regulate our body’s immune responses. These are… Read More

#Cancer Research #Editor's Choice #News

#Immuno-oncology #Immunotherapy #Mouse models

Taconic Biosciences expands immuno-oncology animal model portfolio

Taconic Biosciences, global provider of drug discovery animal model solutions, has expanded its immuno-oncology portfolio. Immuno-oncology is a leading research priority because it uses the body’s own immune system to effectively treat some types of cancer. Syngeneic tumour animal models play a critical role because they use standard inbred mice… Read More

#Cancer Research #News

#Biologics #Cell therapy #CRISPR #Gene therapy #Immuno-oncology

Cognate BioServices announces major US and Europe expansion

Cobra Biologics, the gene therapy division of the Cognate BioServices’ group, has announced a multi-phase expansion of its plasmid DNA services, a continuation of its gene therapy services’ project for viral vectors and plasmid DNA. This includes a four-fold increase in HQ High Quality (HQ) DNA manufacturing capacity alongside new… Read More

#News

#Immuno-oncology #Mouse models #Oncology

Syngeneic mouse models for preclinical immuno-oncology

The advent of immuno-oncology has necessitated changes in the types of animal models used in oncology drug discovery. Syngeneic models—inbred mice bearing an engrafted tumour derived from a genetically identical mouse strain—are invaluable preclinical research tools that enable tumor studies in the context of a complete and functional immune system. Read More

#Resources